MaxWell News
Milestones, science, and momentum from the team building a non-destructive future for AF.
FEATURED
September 2026
MaxWell Biomedical named HFSA Heart Tank Finalist
Selected to pitch at the 2026 HFSA Devices meeting, where emerging heart failure technologies are presented to leading clinicians, investors, and industry experts. We take the stage October 9 in Phoenix, AZ.
LATEST
Progress you can verify.
MaxWell Biomedical Closes New Financing Round
MaxWell Biomedical has closed a new financing round. This funding strengthens our path toward a non-destructive, atrial-focused resynchronization therapy designed to restore coordinated atrial mechanics in people living with AF and heart failure with preserved ejection fraction (HFpEF).
Thank you to the investors who share our conviction, the clinicians pushing the science forward, and the team building what doesn’t yet exist. Onward.
Five Abstracts Accepted at HRS and EHRA 2026
Three posters at the Heart Rhythm Society Scientific Sessions in Chicago and two at the EHRA Congress in Paris.
View publications →MaxWell Biomedical Expands Its Clinical Study
We are expanding our ongoing clinical study of Spatial Resynchronization Therapy (SRT) to include patients with AF and heart failure with preserved ejection fraction (HFpEF).
SRT is an investigational, non-destructive approach designed to terminate AF and support atrial synchrony without the tissue damage of ablation. A broader study means more patients, more data and a stronger scientific foundation.
ARCHIVE
Where we’ve been.
2023 Featured in MedTech Strategist: “AF Symposium 2023: Experts Debate Cosmic Questions”
At AF Symposium 2023, co-founder Randy Werneth spoke with MedTech Strategist about Spatial Resynchronization Therapy (SRT), MaxWell’s investigational pacing-based approach to AF. Electrophysiologist Douglas Packer, MD, said it “may serve as a single modality or a hybrid” alongside ablation.
December 2022 MaxWell Biomedical Completes Acquisition of Cardialen’s Assets
MaxWell acquired the assets of Minneapolis-based Cardialen, including MultiPulse™ Therapy (MPT™), a low-energy defibrillation and cardioversion therapy designed to treat AF and ventricular tachycardia. The acquisition expands MaxWell’s intellectual property portfolio.
Read the announcement →October 2022 Proof-of-Concept Human Study Completes Enrollment
MaxWell completed enrollment in its first-in-human study, “Initial Experience with Spatial Resynchronization Therapy in Patients with Atrial Fibrillation” (NCT05461612), at the Tbilisi Heart and Vascular Clinic in Tbilisi, Georgia.
September 2022 Awarded NIH Phase I SBIR Grant (NHLBI)
MaxWell received a Phase I Small Business Innovation Research grant from the National Heart, Lung, and Blood Institute to support development and testing of its SRT device. Phase I SBIR grants help establish a technology’s technical merit and feasibility.
July 2022 First-in-Human Study Initiated (NCT05461612)
MaxWell launched its first-in-human study of Spatial Resynchronization Therapy, SR-TheAF, at the Tbilisi Heart and Vascular Clinic in Tbilisi, Georgia.
Read the press release →2017 Scientific American: “New Wireless Pacemaker Could Prevent Common Complications”
Scientific American covered a wirelessly powered pacemaker developed by Aydin Babakhani’s team at Rice University, designed to avoid the leads that can cause infection and other complications. Dr. Babakhani later co-authored MaxWell research presented at HRS 2019.
Read on Scientific American →Press releases reflect information available at the time of publication. MaxWell Biomedical’s technologies are investigational and are not available for sale.